Structure/class |
|
Pharmacodynamics |
- Functions at the GABA-A receptor
- In contrast to BZD, it increases the duration of GABA-A channel opening.
- At higher concentrations, it may be GABA-mimetic (that is, they can open the channel themselves)
- Also depress excitatory transmission of glutamate by binding to AMPA channels.
- Also has some non-synaptic membrane effects
Overall, due to their effect on many channels, barbiturates producing more pronounced central depression and having a lower margin of safety than BZDs. They may also be used as induction agents. |
Administration |
- IV
|
Distribution |
- It is very rapidly distributes into and then away from the CNS, which accounts for its quick onset and offset.
|
Metabolism |
- Hepatic, by microsomal enzymes.
- Note that overall, metabolism rate is slow and therefore, accumulation does occur if there is repeated dosing/infusion. It is not suitable for long term sedation, e.g. in ICU.
- Remember that barbiturates are enzyme inducers.
|
Excretion |
- Excreted in the urine mainly as glucuronide derivative.
- One exception is phenobarbital, which is excreted 20-30% unchanged in the urine. Phenobarbital is a weak acid with a pKa of 7.4. Therefore, alkalinizing the urine may increase its elimination significantly.
|
Indications |
- Used to terminate status epilepticus
- Used as an induction agent (e.g. thiopental)
|
Contraindications |
- Absolute CI in porphyria (barbiturates may precipitate porphyria crisis)
|
Special precautions |
- Elderly patient
- Liver disease
|
Interactions |
- Additive effects if given with other CNS drugs (opioids/anti-psychotics/alcohol)
- It is an enzyme inducer, so reduced effects of warfarin/digoxin/carbamazepine
|
Adverse events |
- Extension of its pharmacologic properties – CNS depression and respiratory depression.
|
Dosing/administration |
|
Toxicology |
|
Withdrawal syndrome |
|
Special notes |
|